Enanta Pharmaceuticals, Inc. (ENTA)

NASDAQ: ENTA · IEX Real-Time Price · USD
43.06
-2.18 (-4.82%)
Dec 5, 2022 4:00 PM EST - Market closed
-4.82%
Market Cap 940.88M
Revenue (ttm) 86.16M
Net Income (ttm) -121.76M
Shares Out 20.76M
EPS (ttm) -5.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 104,893
Open 45.12
Previous Close 45.24
Day's Range 42.66 - 45.12
52-Week Range 37.59 - 82.56
Beta 0.53
Analysts Buy
Price Target 71.78 (+66.7%)
Earnings Date Nov 21, 2022

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepat... [Read more]

Industry Biotechnology
IPO Date Mar 21, 2013
CEO Jay Luly
Employees 160
Stock Exchange NASDAQ
Ticker Symbol ENTA
Full Company Profile

Financial Performance

In 2022, ENTA's revenue was $86.16 million, a decrease of -11.24% compared to the previous year's $97.07 million. Losses were -$121.76 million, 54.1% more than in 2021.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for ENTA stock is "Buy." The 12-month stock price forecast is 71.78, which is an increase of 66.70% from the latest price.

Price Target
$71.78
(66.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Enanta Pharmaceuticals to Participate in Two Investor Conferences in November

WATERTOWN, Mass.--( BUSINESS WIRE )--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced ...

1 week ago - Business Wire

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 7.30% and 9.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With...

WATERTOWN, Mass.--( BUSINESS WIRE )--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported fi...

2 weeks ago - Business Wire

Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for It...

WATERTOWN, Mass.--( BUSINESS WIRE )--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced ...

3 weeks ago - Business Wire

Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, ...

2 months ago - Business Wire

Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases,...

2 months ago - Business Wire

Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, ...

2 months ago - Business Wire

New Preclinical Data for EDP-235, Enanta's Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, ...

2 months ago - Business Wire

Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases,...

3 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Co...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, ...

3 months ago - Business Wire

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver di...

3 months ago - Business Wire

Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its F...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases,...

4 months ago - Business Wire

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibi...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

4 months ago - Business Wire

Earnings Preview: Enanta Pharmaceuticals (ENTA) Q3 Earnings Expected to Decline

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?

Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor...

5 months ago - Zacks Investment Research

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver di...

5 months ago - Business Wire

Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) Int...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, ...

5 months ago - Business Wire

Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, ...

6 months ago - Business Wire

Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

6 months ago - Zacks Investment Research

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases,...

6 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research